---
schema_version: "secwatch.filing_event.v1"
accession: "0001401914-26-000052"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2026-10-02T20:01:29+00:00"
generated_at: "2026-10-12T14:35:15.089377+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience gets Nasdaq bid-price deficiency notice, has until March 29, 2027 to regain compliance

## Summary
- Nasdaq notified Daré on September 28, 2026 that DARE's closing bid price was below the $1.00 minimum for 30 consecutive business days.
- Daré has 180 calendar days, until March 29, 2027, to regain compliance under Nasdaq Listing Rule 5550(a)(2); the notice has no immediate listing effect.
- Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- If not cured, Daré may qualify for an additional 180-day period, but failure could lead to delisting and a Nasdaq Hearing Panel appeal.
- Daré said it will monitor its closing bid price and consider options to regain compliance, with no assurance it will succeed.

## SEC filing metadata
- accession: 0001401914-26-000052
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2026-10-02T20:01:29+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000052/0001401914-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000052/dare-20260928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001401914-26-000052
- JSON: https://secwatch.observer/filing/0001401914-26-000052.json
- Plain text: https://secwatch.observer/filing/0001401914-26-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.